Abstract
Malignant hypertension is a severe elevation of blood pressure that results in acute renal damage. An American Medical Association Ad Hoc Subcommittee on Research has defined malignant hypertension as follows: “A clinical phase (of hypertension) rarely occurring de novo, more often appearing after the development of primary or secondary hypertension. It is characterized by established diastolic hypertension usually with a diastolic pressure greater than 140 mm Hg and by accelerated and progressive renal damage usually but not necessarily accompanied by papilledema and often by retinal hemorrhages or exudates, and given to early death in uremia unless the course is terminated along the way by complicating brain or heart damage” (1). Encephalopathy is a transient clinical state associated with malignant nephrosclerosis. It is characterized by headache, vomiting, convulsions, stupor or coma. It is a manifestation of cerebral edema and increased intracranial pressure.
Keywords
- Blood Pressure Control
- Antihypertensive Effect
- Serum Creatinine Concentration
- Malignant Hypertension
- Hypertensive Emergency
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Brust A A, Perera GA, Wilkins RW: Classification of types of hypertension. JAMA 166: 640–641, 1958.
Volhard F, Fahr T: Die Brightsche Nierenkrank-heit. Verlag Von Julius Springer, Berlin, pp 247–280, 1914.
Fahr T: Kurze Beiträge zür Frage der Nephroskele- rose. Deutsche Arch Für Klin Med 134: 366–389, 1920.
Fahr T: Über Nephroskelrose: Pathologioghe ana-tomic des Morbus Brightii. Harnorgane Mannliche Geschlechtsorgan. Verlag Von Julius Springer, Berlin, pp 933–958, 1934.
Giese J: The pathogenesis of hypertensive vascular disease. Munksgard, Copenhagen, 1966.
Bohle A, Grund K, Helmchen U, Meyer D: Primary malignant nephrosclerosis. Clin Sei Mol Med 51 (Suppl 3): 23s–25s, 1977.
Byrom FB: Tension and the artery: the experimental elucidation of pseudo-uremia and malignant neph-rosclerosis. Clin Sci Mol Med 51 (Suppl 3): 3s–11s, 1977.
Goldby FS, Bielin LJ: How an acute change in arterial pressure damages arterioles: electron microscopic changes during angiotensin infusion. Cardio- vasc Res 6: 569–684, 1972.
Sokolow M, Perloff D: Five years survival of consec-utive patients with malignant hypertension treated with antihypertensive agents. Am J Cardiol 6: 858–863, 1960.
Pohle JEF, Thurston H, Swales D: Hypertension with renal impairment: influence of intensive therapy. Q J Med 43: 569–581, 1974.
Woods JW, Blythe WB, Huffines WD: Management of malignant hypertension complicated by renal in-sufficiency: a follow-up study. N Engl J Med 291: 10–13, 1974.
Cordingly FT, Jones NF, Wing AJ, Hilton PJ: Re-versible renal failure in malignant hypertension. Clin Nephrol 14: 98–103, 1980.
Mroczek WJ, Davidov M, Gavrilovitch L, Finnerty FA: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904, 1969.
Perera G: Hypertensive vascular disease. J Chron Dis 1: 33–42, 1955.
Wagener HP, Keith NM: Cases of marked hypertension, adequate renal function and neuroretinitis. Arch Intern Med 34: 374–387, 1924.
Keith NM, Wagener HP, Kernohan JW: The syndrome of malignant hypertension. Arch Intern Med 41: 141–181, 1928.
Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension; their course and prognosis. Am J Med Sci 197: 332–343, 1939.
Sevitt LH, Evan DJ, Wrong OM. Acute oliguric renal failure due to accelerated (malignant) hypertension. Q J Med 40: 127–144, 1971.
Tifft OP, Gavras H, Kershaw G, Gavras I, Brunner HR, Liang C, Chobanian A: Converting enzyme inhibition in hypertensive emergencies. Ann Intern Med 90: 43–47, 1979.
Hodsman GG, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JIS: Factors related to first dose hypotensive effect of Captopril: prediction and treatment. Br Med J 286: 832–834, 1983.
McAllister RG Jr: Guanethidine in hypertensive therapy: experience with an oral loading dose. J Clin Pharmacol 15: 771–778, 1975.
Hertting J, Axelrod J, Patrick RW: Actions of bretylium and guanethidine on the uptake and release of [3H]-noradrenalin. Br J Pharmacol 18: 161–166, 1962.
Woosley RL, Nies AS: Drug therapy: guanethidine. N Engl J Med 295: 1053–1058, 1979.
Dranov J, Skyler JS, Gunnells JC: Malignant hypertension. Arch Intern Med 133: 791–801, 1974.
Manual of Medical Therapeutics, 23rd ed., Chapter 7. Little, Brown and Co, Boston, p 171, 1980.
Wilkinson EL, Backman H, Hect H: Cardiovascular and renal adjustments to a hypotensive agent (1- hydrazinophthalazine Ciba BA 5868;apresoline). J Clin Invest 31: 872–879, 1952.
Koch-Weser J: Drug therapy: diazoxide. N Engl J Med 294: 1271–1274, 1976.
Kanada SA, Kanada DJ, Hutchinson RA, Wu D: Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med 84: 696–698, 1976.
Anderson RJ, Hart GR, Crumpler CP, Reed WG, Matthews CA: Oral Clonidine loading in hypertensive urgencies. JAMA 246: 845–853, 1981.
Lowenthal DT: Pharmacokinetics of Clonidine. J Cardiovasc Pharmacol 2 (Suppl l): 529–537, 1981.
Velasquez MT, Rho J, Maronde RF, Barr J: Plasma Clonidine levels in hypertension. Clin Pharmacol Ther 35: 345–357, 1983.
Burns J, D’Angelo LJ: Complications of clonindine suppression test for pheochromocytoma. Letters: N Engl J Med 307: 756–757, 1982.
Freis E: Reserpine in hypertension: present status. AFP 11 (No 6): 120–122, 1975.
Guazzi MD, Polese A, Fiorentini C, Bartorelli A, Motuzzi P: Treatment of hypertension with calcium antagonists; review Hypertens 5 (Suppl 2): 85–91, 1983.
Magometschnigg D: Acute hypotensive response to nifedipine. Hypertension 5 (No 2): 80–85, 1983.
Cotrell JE, Casthely P, Brodie JD, Patel K, Klein A, Turndorf H: Prevention of nitroprusside-induced cyanide toxicity with hydroxocobalamine. N Engl J Med 298: 809–811, 1978.
Cummings AM, Brown J J, Frasher RR, Lever AT, Norton JS, Richards DA, Robertson JTS: Blood pressure lowering by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol 8: 359–364, 1979.
Wilson DJ, Wallon JD, Vlachakis ND, Freis E, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland M: Intravenous labetalol in treatment of hypertension and hypertensive emergencies. Am J Med (Suppl Oct 17 ): 95–103, 1983.
Maronde RF, Robinson D, Vlachakis ND, Barr J, Chung M, Zampaglione N, Medakovic M: Study of single and multiple dose pharmacokinetic/phar-macodynamic modeling of antihypertensive effects of labetalol. Am J Med (Suppl Oct 17 ): 40–47, 1983.
Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Shelton J: A comparison of the effects of hydro-chlorothiazide and furosemide in the treatment of hypertensive patients. Q. J. Med 40: 541–560, 1971.
Reigger G A, Steilner H, Haijduk K, Liebau G: Cap-topril in the long-term treatment of essential hyper-tension; changes in the renin-angiotensin-aldoste- rone system. Am J Cardiol 49: 1555–1557, 1982.
VA Cooperative Study Group on Antihypertensive Agents: Propranolol in the treatment of essential hypertension. JAMA 237: 2303–2310, 1977.
Schumacker GE: Using pharmacokinetics in drug therapy. V. Contributions to developing dosage regi-mens for antihypertensive drugs. Am J Hosp Pharm 36: 1222–1226, 1979.
Laragh JH, Ulick S, Januszewicz V, Deming GB, Kelly WC, Lieberman S: Aldosterone secretion in primary and malignant hypertension. J Clin Invest 39: 1091–1106, 1960.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Maronde, R.F., Robinson, D.C. (1986). The Treatment of Malignant Hypertension. In: Maronde, R.F. (eds) Topics in Clinical Pharmacology and Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4864-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4864-4_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-9336-1
Online ISBN: 978-1-4612-4864-4
eBook Packages: Springer Book Archive